Hansoh Pharmaceutical Group Company Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
Hansoh Pharmaceutical Group Company Stock Forecast and Price Target
Hansoh Pharmaceutical Group Company's most recent price target of HK$16.56 for 2024 was provided by seven renowned analysts over the past few months, with an average prediction of HK$16.56. If this prediction is correct, Hansoh Pharmaceutical Group Company's stock could fall by -1.43 percent from its current trading price. The potential decrease for the stock is HK$16.56 per share, with a possible range of HK$13.66 to HK$25.83.
-1.43% Downside
Hansoh Pharmaceutical Group Company Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Hansoh Pharmaceutical Group Company's Price has decreased by 100.00%, from HK$25.33 to HK$0.00. For next year, analysts predict Fair Value of HK$0.00, which would mean an increase of 100.00%. Over the next six years, experts predict that Hansoh Pharmaceutical Group Company's Fair Value will grow at a rate of 100.00%.
Hansoh Pharmaceutical Group Company Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Hansoh Pharmaceutical Group Company's Revenue has grown by 7.97%, rising from HK$8.69B to HK$9.38B. For the next year, 0 analysts project Hansoh Pharmaceutical Group Company's Revenue to drop by 0.25%, reaching HK$9.36B. By 2030, professionals believe that Hansoh Pharmaceutical Group Company's Revenue will decrease by 0.17%, reaching HK$9.37B – a concerning trend for the company.
.jpg)
Hansoh Pharmaceutical Group Company Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Hansoh Pharmaceutical Group Company's Dividend per Share has grown, rising from HK$0.07 to HK$0.09 – a growth of 28.57%. According to 0 prominent analysts, Hansoh Pharmaceutical Group Company's Dividend per Share will fall by 14.81% in the next year, reaching HK$0.08. By 2030, professionals believe that Hansoh Pharmaceutical Group Company's Dividend per Share will decrease by 13.73%, reaching HK$0.08 – a concerning trend for the company.
Hansoh Pharmaceutical Group Company EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Hansoh Pharmaceutical Group Company's EBITDA has seen a drop from HK$2.99B to HK$2.93B – a 1.92% decrease. In the next year, analysts believe that EBITDA will reach HK$3.00B – an increase of 2.44%. For the next eight years, the forecast is for EBITDA to grow by 2.51%.
Hansoh Pharmaceutical Group Company EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Hansoh Pharmaceutical Group Company's EBIT has gone down from HK$2.77B to HK$2.61B – a 5.97% drop. For the next year, analysts predict that EBIT will reach HK$2.73B – an increase of 4.88%. Over the next eight years, experts believe that Hansoh Pharmaceutical Group Company's EBIT will grow at a rate of 5.06%.
Hansoh Pharmaceutical Group Company EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Hansoh Pharmaceutical Group Company's EPS has decreased by 100.00%, from HK$0.44 to HK$0.00. For next year, analysts predict EPS of HK$0.00, which would mean an increase of 100.00%. Over the next six years, experts predict that Hansoh Pharmaceutical Group Company's EPS will grow at a rate of 100.00%.
Site Navigation
.jpg)